2010 Future Medicine Ltd. Cite this: Anti-TNF-α Agents in the Treatment of Immune-mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls - Medscape - Nov 01, 2010.

who receive tumor necrosis factor (TNF) inhibitors after being diagnosed with early-stage colorectal, lung, or prostate cancer have similar survival outcomes as those who receive conventional ...

The study compared overall deaths, and deaths due to cancer, among patients using TNF inhibitors vs. those on conventional synthetic disease-modifying anti-rheumatic drugs. The researchers ...

Because of this, TNF inhibitors are often a first choice in a biologic. Five anti-TNF agents are approved for use in RA, each with different properties and mechanisms, but all of which block or ...

Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform ...